Anastrozole

Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors

...ients who are treated with the aromatase inhibitor anastrozole or with tamoxifen. Researchers from the Royal Ma...ly stage breast cancer patients planned for either anastrozole or tamoxifen treatment." The study assesse...itive (p=0.003) patients. The greater efficacy of anastrozole observed in the parent ATAC trial and the similar ...

Patient management: Quality of life and beyond

...urvival Abstract #1136, Shozo Ohsumi, M.D., Ph.D. Embargo: 5:30 p.m. CST, December 11, 2008 After one to four years of tamoxifen, switching to anastrozole improves disease-free survival by about 31 percent, but patients pay a price in quality of life measures. The difference in quality of life is signifi...

Hot Flashes, Night Sweats a Good Sign for Breast Cancer Patients

...mptoms at their first follow-up visit during a trial assessing tamoxifen or anastrozole for adjuvant therapy of postmenopausal breast cancer. The 37.5 percent o...anastrozole. Overall, patients with and without these symptoms who received anastrozole had lower recurrence rates than those who received tamoxifen. The study ...

Breast Cancer Drug Not Tied to Cognitive Decline: Study

...ing is 'good news' for postmenopausal women taking anastrozole TUESDAY, Sept. 2 (HealthDay News) -- C...previous study results, the cancer prevention drug anastrozole does not appear to cause impairment of cognitive performance, a new study found. anastrozole has been shown to be superior to tamoxifen in prev...

Hormone Drug Type Makes Survival Difference in Advanced Breast Cancer

...trogen stimulates tumor growth. Aromatase inhibitors work by limiting a woman’s production of estrogen. Several aromatase inhibitors, including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara) have been available for clinical use for the past decade or so. Other breast cancer tre...

Breast Cancer may no longer be a killer disease

...er Campaign, said, "Women now had a much better chance of surviving breast cancer. "As well as drugs like Herceptin and aromatase inhibitors such as anastrozole and letrozole, patients can also benefit from better cosmetic results which can have a significant psychological impact. "While a cure for everyon...

Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings

...statistically significant since patients on Arimidex alone have their survival prolonged to 23.9 months. Additional data showed that introducing anastrozole instead of Tamoxifen in early hormone sensitive breast cancer among postmenopausal women increased their chances of avoiding disease recurrence. S...

Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer

... Researchers have found that aromatase inhibitors like anastrozole are more effective in treating postmenopausal women with hormone receptor-p...n with early breast cancer for more than 5 years and found that patients on anastrozole had much less adverse effects and the drug was well tolerated by patients. ...

More Breast cancer Cases Diagnosed In The UK

...the recurrence of the disease. The benefits derived from both tamoxifen and anastrozole are being studied. The DCIS is considered a pre-cancerous condition, which ...not taking drugs which are capable of preventing the cancer from returning. anastrozole is reported to be more effective than tamoxifen when it comes to reducing t...

Anastrozole Is A More Effective Cancer Drug

...e deaths among the 2,009 women who changed over to anastrozole was 66, while in the case of tamoxifen, it was 90. AstraZeneca is marketing anastrozole as Arimidex, and this has received the support of ...urrence of breast cancer by 50%, and administering anastrozole reduces it by a further 26%. In the UK alone...

Anastrozole in Medical Technology

Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports

...arian suppression, and randomly assigned into one of four study groups: (1) anastrozole plus Zometa; (2) anastrozole alone; (3) tamoxifen plus Zometa; (4) tamoxifen alone. The treatment period...

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

...ancer Index in women with breast cancer randomized to receive five years of treatment with tamoxifen or two years of tamoxifen followed by three years anastrozole treatment. The researchers found that the Theros Breast Cancer Index will identify, among patients with early stage breast cancer, those with a higher...

Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis

...lower than for which AstraZeneca has already established two-year chronic use safety data in their breast cancer prevention trials and is cited in the anastrozole product label. These data will advance development of MPI-676 and help us bring this important new treatment to women suffering from endometriosis, a ...

Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer

...arian suppression, and randomly assigned into one of four study groups: (1) anastrozole plus Zometa; (2) anastrozole alone; (3) tamoxifen plus Zometa; (4) tamoxifen alone. The treatment period...

Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousands of Women

...sal women with early breast cancer, reinforce that anastrozole can help many more women live cancer-free, for longer. For the first time, anastrozole has been shown to be the only treatment of its typ...a woman's treatment ends, the protective effect of anastrozole in reducing the risk of hormone-sensitive early br...

Anastrozole Confirmed Superior in Breast Cancer Prevention

... SAN ANTONIO, Dec. 14 /PRNewswire/ -- anastrozole is more effective than tamoxifen at preventing bre... tamoxifen with 5 years of the aromatase inhibitor anastrozole for the treatment of postmenopausal women with inv...e completion of treatment), patients who had taken anastrozole continued to show reduced rates of tumor recurrenc...

Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen

...nificantly improved by switching from tamoxifen to anastrozole (Arimidex). An analysis of the 'Arimidex'-'Nolvade...I). The study demonstrated that women switching to anastrozole (n=489) rather than remaining on tamoxifen (n= 490...opportunity to receive an aromatase inhibitor like anastrozole immediately after surgery and chemotherapy to prov...

First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex

... anastrozole (ArimidexTM) improves overall survival in postmeno...nificantly improved by switching from tamoxifen to anastrozole (ArimidexTM). An analysis of the ‘Arimidex&r...I). The study demonstrated that women switching to anastrozole (n=489) rather than remaining on tamoxifen (n= 490...

Anastrozole in Biological News

Mayo Clinic research on tamoxifen leads to recommendation for CYP2D6 gene test

...followed by three years of anastrozole, an aromatase inhibitor. The initial results of ABCSG-8, reported in 2005, concluded that women who switched to anastrozole had a 40 percent reduced risk of breast cancer recurrence compared to staying on tamoxifen. The aim of the new study was to determine whether CYP...

New research shows no link between aromatase inhibitors and cardiovascular problems

...his was important and reassuring news for women. AIs, such as letrozole, anastrozole and exemestane, work by causing severe oestrogen deprivation and, increasin...ascular events in comparison to tamoxifen is not significant for letrozole, anastrozole or exemestane. Furthermore, the frequency of fatal heart attacks in the ...

Anastrozole in Biological Technology

Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium

...ntation (General Session 5): "Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study" Presenter: Mitch Dowsett, Ph.D., Royal Marsden Hospital, London Location: Exhibit Hall D Abou...

Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress

...pe DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study" -- "GRB7-dependent pathways a...edict response to neoadjuvant endocrine therapy including tamoxifen and anastrozole at the ASCO Breast Cancer Symposium in September. Conference Call Det...

Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca

...ct profile and duration of treatment. "I am pleased that Meditrina will be pursing this indication, leveraging the work done to date by AstraZeneca. anastrozole in combination with an estrogen and progestin in the area of women's gynecologic indications represents a valid medical approach and sits well with Me...